Elizabeth Parrish
Elizabeth Parrish commonly known as Liz Parrish (born 30th January 1971) is an entrepreneur, founder and CEO of BioViva, American biotechnology gene therapy company. She is widely known for receiving experimental Anti-aging gene therapies developed by her own company in the late 2015.[1][2][3][4][5]
Contents
Early Life & Education
Parrish was born in Portland, Oregon and raised with her two older brothers. At her young age, Parrish’s parents divorced and she lived with her father in Seattle, Washington State. In 1997, Parrish joined the Seattle Central Collage and graduated with honors in AS/Science. Though, Parrish received acceptance to the university of Washington in 1999, she didn’t start attending classes until 2001 because she gave birth in 1999. Parrish received her MBA in 2022 from Buckinghamshire University.[6]
Career
Between 2013 and 2016, Parrish held the role of Secretary on the Board of Directors for the Regenerative Technology Alliance, a non-profit industry group. From 2013 to 2018, she was the Chief Marketing Officer and Media Officer at RNAx LTD. In 2014, Parrish established BioViva Inc. and has continued to serve as the Chief Executive Officer of the company since then.
Experimental gene therapy
Motivated by her son's Type 1 diabetes diagnosis, in September 2015 Parrish 44-year-old at the time decided to undergo experimental anti-aging gene therapies that had not been tested on humans before, only on mice. To access these unapproved treatments, Parrish traveled from the US to Colombia, where she could bypass FDA regulations. At an unspecified clinic in Colombia, Parrish received two experimental therapies. The first was a myostatin inhibitor - a drug shown in animal studies to increase muscle mass by blocking the protein that inhibits muscle growth. The second was a gene therapy using viruses to deliver genetic material for telomerase, a protein that extends telomeres. Telomeres are the protective caps on the ends of DNA strands called chromosomes, which contain genetic information. In young humans, telomeres are typically 8,000-10,000 nucleotides long, but they shorten with each cell division until they reach a critical length, causing the cell to stop dividing or die.
Results of the therapy
Prior to receiving the therapies, tests conducted by SpectraCell showed that Parrish's telomeres were unusually short for her age, putting her at higher risk of age-related diseases at a younger than typical timeframe. In March 2016, follow-up tests by SpectraCell revealed that her telomeres had lengthened by approximately 20 years. This suggests Parrish had become biologically younger as a result of the therapies. These findings were independently verified by the non-profit organization HEALES (Healthy Life Extension Company) based in Brussels, as well as the UK-based Biogerontology Research Foundation, a charity dedicated to combating age-related diseases.
Post Experiment
This experimental case involving Parrish was presented at the Longevity World Forum, an international conference on healthy aging that took place for the second time in Valencia.
Prior to the treatment, Parrish was 44 years old chronologically, but her biological age was 64 years old. Immediately after receiving the experimental therapies, her biological age became aligned with her chronological age of 44. Now, Parrish's biological age is 20 years younger than her actual chronological age of 44.
Publications
- Expressive Origins: Tales of How Two Strands DNA Impact Health and Longevity[7]
- New intranasal and injectable gene therapy for healthy life extension[8]
- Safety Study of AAV hTERT and KLOTHO gene transfer therapy for dementia[9]
- Biosimilar Gene Therapy: Investigational Assessment of Secukinumab Gene Therapy[10]
Experimental anti-aging gene therapy
Main article: BioViva
Motivated by her son's Type 1 diabetes diagnosis, in September 2015 Parrish 44-year-old at the time underwent experimental anti-aging gene therapies that had not been tested on humans before, only on mice. To access these unapproved treatments, Parrish traveled from the US to Colombia, where she could bypass FDA regulations
References
- ↑ "Could gene therapy help you live forever? CEO of controversial firm claims she has successfully carried out first anti-ageing treatment - on herself". https://www.dailymail.co.uk/sciencetech/article-3559947/Could-gene-therapy-help-live-forever-CEO-controversial-firm-claims-successfully-carried-anti-ageing-treatment-herself.html.
- ↑ Mohammadi, Dara; Davis, Nicola (2016-07-24). "Can this woman cure ageing with gene therapy?" (in en-GB). The Observer. ISSN 0029-7712. https://www.theguardian.com/science/2016/jul/24/elizabeth-parrish-gene-therapy-ageing.
- ↑ Chace, Calum. "Extending Health Spans By Extending Telomeres: Profile Of Liz Parrish" (in en). https://www.forbes.com/sites/calumchace/2022/10/21/extending-health-spans-by-extending-telomeres-profile-of-liz-parrish/.
- ↑ "Liz Parrish Is Patient Zero in Her Own Anti-Aging Experiment" (in en). https://www.discovermagazine.com/health/liz-parrish-is-patient-zero-in-her-own-anti-aging-experiment.
- ↑ "First Data from Anti-Aging Gene Therapy" (in en). https://www.the-scientist.com/first-data-from-anti-aging-gene-therapy-33661.
- ↑ "Elizabeth Parrish CEO, BioViva". 2024-05-21. http://www.healthclubmanagement.co.uk/health-club-management-features/Elizabeth-Parrish/33283.
- ↑ "Expressive Origins: Tales of How Two Strands DNA Impact Health and Longevity". https://www.hamiltonplace.com/products/product/expressive-origins-tales-of-how-two-strands-dna-impact-health-and-longevity-barnesnoble-503199.
- ↑ Jaijyan, Dabbu Kumar; Selariu, Anca; Cruz-Cosme, Ruth; Tong, Mingming; Yang, Shaomin; Stefa, Alketa; Kekich, David; Sadoshima, Junichi et al. (2022-05-17). "New intranasal and injectable gene therapy for healthy life extension" (in en). Proceedings of the National Academy of Sciences 119 (20). doi:10.1073/pnas.2121499119. ISSN 0027-8424. PMC PMC9171804. PMID 35537048. https://pnas.org/doi/10.1073/pnas.2121499119.
- ↑ "Home" (in en). https://www.maplespub.com/.
- ↑ "Biosimilar Gene Therapy: Investigational Assessment of Secukinumab Gene Therapy". https://www.celljournal.org/article_250608.html.
